Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
Sutro Biopharma, Inc. (STRO), a Delaware corporation, filed this Current Report on Form 8-K on February 28, 2020. The filing details the entry into a material definitive loan and security agreement to secure financing for working capital and general business requirements.
Key Financial Metrics and Debt Structure
- Total Facility Size: Up to $30.0 million in term loans ($25.0 million Term A + $5.0 million Term B).
- Initial Drawdown: $25.0 million borrowed immediately upon execution.
- Use of Proceeds: Approximately $9.6 million was used to repay a prior loan agreement dated August 4, 2017; the remainder is for working capital.
- Interest Rate: Floating rate equal to the greater of 8.07% or (30-day LIBOR or 1.67%, whichever is higher) plus 6.40%.
- Repayment Terms: Interest-only payments through March 1, 2022, followed by 24 equal monthly principal and interest payments. Maturity date is March 1, 2024.
- Final Payment: A fee of 3.83% of the original principal amount is due at maturity or upon prepayment.
- Prepayment Fees: 3.00% if prepaid within the first year, 2.00% in the second year, and 1.00% thereafter.
- Collateral: Secured by all company assets except intellectual property.
Material Changes and Conditions
The company replaced its prior debt facility with this new agreement. A key material condition is the availability of an additional $5.0 million "Term B Loan," which is contingent upon the closing of a new collaboration agreement with an upfront payment of at least $50.0 million. This additional draw must occur by December 31, 2020, or 30 days after the milestone event, whichever is earlier.
Equity Issuance and Covenants
In connection with the loan, the company issued warrants to the lenders for 81,257 shares of common stock at an exercise price of $9.23 per share. The warrants are immediately exercisable and expire on February 28, 2030. The agreement includes restrictive covenants prohibiting dividends or distributions on capital stock and limits on additional indebtedness. An event of default includes any material adverse change in the company's business or operations.
Investor Verification Checklist
- Verify the exact amount of cash remaining after the $9.6 million repayment of the prior loan.
- Monitor progress toward the $50.0 million collaboration milestone required to access the additional $5.0 million Term B Loan.
- Review the full text of the loan agreement and warrants filed as exhibits to the 2019 Form 10-K for detailed covenant language.
- Assess the impact of the 3.83% final payment fee and potential prepayment fees on future liquidity.